Articles written by Vandana Singh - Benzinga

Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasons

House Judiciary subpoenas ex-Pfizer exec Philip Dormitzer amid claims the COVID-19 vaccine announcement was delayed to avoid influencing the 2020 election.

Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

RFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine Approval

FDA vaccine head Vinay Prasad restricted Moderna and Novavax COVID vaccines to high-risk groups, overriding staff advice amid concerns about rare side effects.

AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ivonescimab.

Palantir Reportedly Assisting Trump Administration's DOGE To Compile Americans' Personal Data

Several states are suing the federal government, alleging that CMS illegally shared Medicaid data with DHS, violating federal law and risking public health outcomes.

Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma

FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial.

Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial data.

How Zevra's Miplyffa Could Transform Investment Strategies

HC Wainwright sees Zevra's Miplyffa launch and EU plans driving upside, initiating coverage with a $26 target and Buy rating on rare disease strength.

Merck's Hypertension Drug On FDA Fast Track For Label Expansion

Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact.

Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasons

House Judiciary subpoenas ex-Pfizer exec Philip Dormitzer amid claims the COVID-19 vaccine announcement was delayed to avoid influencing the 2020 election.

Cava Analyst Says Stock Viewed As Pricy But Worth It

KeyBanc initiates Cava with Overweight, citing growth potential, brand upside, and strong fundamentals despite premium valuation.

Centene's Guidance Withdrawal Spooks Sector, Oscar Health Stock Falls

Oscar Health shares dip as Centene withdraws 2025 guidance citing elevated market morbidity; Oscar reaffirms its full-year outlook after Q1 beat.

Trump-Administration's Health Agency Overstepped Authority, Reorganization Unlawful: Court

A federal judge halted the Trump-era HHS overhaul after states argued it violated law and risked harming health programs serving millions.

Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress

Aardvark's lead drug ARD-101 targets PWS and HO with trials underway and funding secured through 2027 after a $94.2 million IPO in February.

Airline Stocks Face Flat Q2—But 1 Thing Could Lift Them

BofA expects Q2 airline earnings to meet outlooks but flags weak demand trends and cautious investor sentiment heading into the second half.

Avadel Shareholder Seeks Board Shakeup, Citing Millions Lost On Lumryz

ASL demands Avadel replace its board over failures in marketing Lumryz and urging a review of strategic options

Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

Atai and Beckley report that a single dose of BPL-003 reduced depression symptoms significantly and safely in treatment-resistant patients.

Johnson & Johnson's Drug Discount Plan Gets Thrown Out In Court

A federal court denied Johnson & Johnson's motion to implement a 340B drug rebate model, siding with HHS and hospitals who argued it violated program intent.

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor

Mesoblast plans to file a BLA for Revascor by year-end after aligning with FDA on trial design, potency assays, and manufacturing controls.